- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05536752
QA102 Fas II-studie i försökspersoner med torr AMD (AMEND)
En fas 2, dubbelmaskad, randomiserad, placebokontrollerad, dos-respons-studie som utvärderar säkerheten och effekten av QA102 hos patienter med torr åldersrelaterad makuladegeneration (AMD)
This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of soft drusen, visual acuity (VA), and geographic atrophy (GA) or choroidal neovascularization (CNV) or the progression of GA in subjects with intermediate to advanced dry AMD.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Approximately 30 sites will randomize a total of approximately 150 subjects to 1 of 3 treatment arms in a 1:1:1 ratio (50 subjects per arm). Each subject will receive either QA102 or matching placebo BID for up to 15 months.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
Arizona
-
Phoenix, Arizona, Förenta staterna, 85021
- Associated Retina Consultants
-
-
California
-
Mountain View, California, Förenta staterna, 94040
- Northern California Retina Vitreous Associates Medical Group
-
Pasadena, California, Förenta staterna, 91107
- California Eye Specialists Medical Group
-
Redlands, California, Förenta staterna, 91107
- California Eye Specialists Medical Group
-
-
Colorado
-
Colorado Springs, Colorado, Förenta staterna, 80909
- Retina Consultants of Southern Colorado, P.C.
-
-
Florida
-
Deerfield Beach, Florida, Förenta staterna, 33064
- Advanced Research
-
Fort Myers, Florida, Förenta staterna, 33912
- National Ophthalmic Research Institute
-
Miami, Florida, Förenta staterna, 33143
- MedEye Associates
-
Pensacola, Florida, Förenta staterna, 32503
- Retina Specialty Institute
-
Pinellas Park, Florida, Förenta staterna, 33782
- Eye Associates of Pinellas
-
Sarasota, Florida, Förenta staterna, 34239
- Sarasota Retina Institute
-
Winter Haven, Florida, Förenta staterna, 33880
- Vitreous and Retina Consultants
-
-
Georgia
-
Marietta, Georgia, Förenta staterna, 30060
- Marietta Eye Clinic
-
-
Illinois
-
Oak Forest, Illinois, Förenta staterna, 60452
- University Retina and Macula Associates
-
-
Louisiana
-
West Monroe, Louisiana, Förenta staterna, 71291
- Northeast Louisiana dba Haik Humble Eye Center
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21209
- The Retina Care Center
-
Hagerstown, Maryland, Förenta staterna, 21740
- Cumberland Valley Retina Consultants
-
Hagerstown, Maryland, Förenta staterna, 21740
- Mid Atlantic Retina Specialists
-
-
Massachusetts
-
Worcester, Massachusetts, Förenta staterna, 01605
- Vitreo-Retinal Associates, P.C.
-
-
Missouri
-
St Louis, Missouri, Förenta staterna, 63144
- Retina Research Institute
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45202
- Velocity Clinical Research
-
-
Oregon
-
Eugene, Oregon, Förenta staterna, 97401
- Verum Research, LLC
-
-
Pennsylvania
-
Erie, Pennsylvania, Förenta staterna, 16507
- Erie Retina Research
-
-
Texas
-
Abilene, Texas, Förenta staterna, 79606
- Retina Research Institute of Texas
-
Austin, Texas, Förenta staterna, 78705
- Austin Research Center for Retina
-
Dallas, Texas, Förenta staterna, 75243
- AXIS Clinicals LLC / Retina of North Texas
-
Plano, Texas, Förenta staterna, 75075
- Texas Retina Associates - Plano
-
San Antonio, Texas, Förenta staterna, 78215
- San Antonio Eye Center
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84107
- Rocky Mountain Retina Consultants
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria:
- Subject must be able to understand and willing to sign a written informed consent form (ICF) prior to the initiation of any study-specific procedures.
- Subject must be age ≥50 years at the time of informed consent.
- Subject must be able to take oral medications and willing to record daily adherence to taking their assigned capsules.
- Subject must have adequate hematologic function, hepatic function, renal function and coagulation profile as defined in the protocol.
- Subject must be willing and able to comply with study procedures and examinations.
Specific to the Study Eye:
-
Subject must have one of the following:
- extensive intermediate-size drusen, or at least 1 large drusen, or
- GA ((not involving the foveal center point) secondary to AMD, with very limited aggregate size of total GA(s), as defined in the protocol.
-
Subject must be able to correctly identify ≥35 ETDRS letters (approximately 20/200 Snellen equivalent).
Specific to Fellow Eye:
- Subject must have a diagnosis of advanced AMD (evidence of GA and/or CNV), to be confirmed by the CRC.
Specific to Both Eyes:
- Subject must have visualizable retina, clear ocular media, and adequate pupillary dilation to ensure high-quality fundus imaging.
Key Exclusion Criteria:
- Subject received an active investigational drug within 6 weeks (or 5 half-lives of the active, whichever is longer) prior to screening for this QA102 study.
- Subject has ever received gene therapy (for any condition).
- Subject is unwilling to stop intake of Age-Related Eye Disease Studies (AREDS) vitamins for the duration of the study.
- Subject has a clinically significant systemic disease that might interfere with the study, in the judgment of the Investigator.
- Subject had major surgery within 30 days prior to Screening.
Specific to Study Eye:
- Subject has large GA, subfoveal GA, or active or inactive CNV, as confirmed by the CRC.
- Subject has GA or CNV due to causes other than AMD that that developed between Visit 1 (Screening) and Visit 2 (Randomization).
- Subject has endophthalmitis.
- Subject has a hemorrhagic or serous pigment epithelial detachment (PED) within 500 µm of the foveal center point, to be confirmed by the CRC.
- Subject has had retinal procedures or surgeries, or has a retinal pathology, such as a macular hole.
- Subject has aphakia or absence of the posterior capsule.
- Subject has ever received, whether in an interventional trial or by prescription, an FDA- approved treatment for GA. Use of such treatment during the QA102 study period also is prohibited. (Study Eye Only)
Specific to Fellow Eye:
Subject has monocular vision impairment, defined as having no light perception in the fellow eye with adequate vision in the study eye.
Specific to Either Eye:
- Subject had intraocular surgery with lens replacement within 3 months of Screening.
- Subject has any ophthalmic condition that could require surgery during the study period.
- Subject has an ocular condition that might affect adequate imaging of the retina and/or or alter visual acuity.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: QA102 200mg group
Subjects randomized to this arm will receive one (1) 200 mg capsule of QA102 and 1 placebo capsule BID = daily dose of 400 mg QA102 for up to 15 months |
Capsules |
|
Experimentell: QA102 400mg group
Subjects randomized to this arm will receive two (2) 200 mg capsules of QA102 BID = daily dose of 800 mg QA102 for up to 15 months |
Capsules |
|
Placebo-jämförare: Placebo group
Subjects randomized to this arm will receive two (2) placebo capsules BID = daily dose of 0 mg QA102 for up to 15 months |
Capsules |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change From Baseline in Soft Drusen Volume (mm3)
Tidsram: Month 12
|
Change from baseline in soft drusen volume (mm3), Efficacy-Evaluable Analysis Set |
Month 12
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Mean Rate of GA Growth
Tidsram: Month 12
|
Mean Rate of Growth in GA (mm2) (Square Root Transformation) from Baseline |
Month 12
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- QA102-CS201
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .